Friday, July 24, 2026
FDA Approves Lytenava for Wet AMD
The FDA has approved Lytenava (bevacizumab-vikg; Outlook Therapeutics) for the treatment of neovascular age-related macular degeneration, making it the first FDA-approved ophthalmic formulation of bevacizumab in the United States.


